Your browser doesn't support javascript.
loading
Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.
Pasvolsky, Oren; Saliba, Rima M; Ledesma, Celina; Popat, Uday R; Alousi, Amin; Olson, Amanda; Oran, Betul; Hosing, Chitra; Bashir, Qaiser; Qazilbash, Muzaffar H; Short, Nicholas J; Ravandi, Farhad; Champlin, Richard; Shpall, Elizabeth J; Kebriaei, Partow.
Afiliação
  • Pasvolsky O; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Saliba RM; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
  • Ledesma C; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Alousi A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Olson A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Oran B; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Hosing C; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Champlin R; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Shpall EJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 98(2): E35-E37, 2023 02.
Article em En | MEDLINE | ID: mdl-36502492
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos